Literature DB >> 26176568

Utility of the Multinational Association for Supportive Care in Cancer (MASCC) Risk Index Score as a Criterion for Nonadmission in Febrile Neutropenic Patients with Solid Tumors.

Roger A Bitar1.   

Abstract

Febrile neutropenic episodes in patients with solid tumors were identified electronically from 10/1/2008 to 11/15/2010. Inclusion criteria were met in 198 episodes. Sensitivity, specificity, and positive and negative predictive values of the MASCC risk index score vs complications were, respectively, 94%, 29.6%, 57.7%, and 82.9%. An MASCC risk index score of 21 or greater could not be used as a criterion for "no complication/ do not admit." Inability to eat should be an admission criterion.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26176568      PMCID： PMC4500479          DOI： 10.7812/TPP/14-188

Source DB:  PubMed          Journal:  Perm J        ISSN： 1552-5767


  19 in total

1.  Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.

Authors:  Jean Klastersky; Marianne Paesmans; Aspasia Georgala; Frédérique Muanza; Barbara Plehiers; Laurent Dubreucq; Yassine Lalami; Michel Aoun; Martine Barette
Journal:  J Clin Oncol       Date:  2006-09-01       Impact factor: 44.544

2.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

3.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

Authors:  J Klastersky; M Paesmans; E B Rubenstein; M Boyer; L Elting; R Feld; J Gallagher; J Herrstedt; B Rapoport; K Rolston; J Talcott
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

4.  Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer.

Authors:  E B Rubenstein; K Rolston; R S Benjamin; J Loewy; C Escalante; E Manzullo; P Hughes; B Moreland; A Fender; K Kennedy
Journal:  Cancer       Date:  1993-06-01       Impact factor: 6.860

5.  Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.

Authors:  Christopher R Flowers; Jerome Seidenfeld; Eric J Bow; Clare Karten; Charise Gleason; Douglas K Hawley; Nicole M Kuderer; Amelia A Langston; Kieren A Marr; Kenneth V I Rolston; Scott D Ramsey
Journal:  J Clin Oncol       Date:  2013-01-14       Impact factor: 44.544

6.  Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.

Authors:  Helen Innes; Sheow Lei Lim; Allison Hall; Su Yin Chan; Neeraj Bhalla; Ernest Marshall
Journal:  Support Care Cancer       Date:  2007-09-25       Impact factor: 3.603

7.  Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia.

Authors:  Linda S Elting; Charles Lu; Carmelita P Escalante; Sharon H Giordano; Jonathan C Trent; Catherine Cooksley; Elenir B C Avritscher; Ya-Chen Tina Shih; Joe Ensor; B Nebiyou Bekele; Richard J Gralla; James A Talcott; Kenneth Rolston
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

8.  Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration.

Authors:  W T Hughes; P A Pizzo; J C Wade; D Armstrong; C D Webb; L S Young
Journal:  Clin Infect Dis       Date:  1992-11       Impact factor: 9.079

Review 9.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.

Authors:  R C Bone; R A Balk; F B Cerra; R P Dellinger; A M Fein; W A Knaus; R M Schein; W J Sibbald
Journal:  Chest       Date:  1992-06       Impact factor: 9.410

10.  Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients.

Authors:  Carmen P Escalante; Mary Ann Weiser; Ellen Manzullo; Robert Benjamin; Edgardo Rivera; Tony Lam; Vi Ho; Rosalie Valdres; Eva Lu Lee; Noemi Badrina; Sally Fernandez; Yvette DeJesus; Kenneth Rolston
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603
View more
  7 in total

1.  Predicting in-hospital mortality of patients with febrile neutropenia using machine learning models.

Authors:  Xinsong Du; Jae Min; Chintan P Shah; Rohit Bishnoi; William R Hogan; Dominick J Lemas
Journal:  Int J Med Inform       Date:  2020-04-15       Impact factor: 4.046

Review 2.  Rapid Fire: Infectious Disease Emergencies in Patients with Cancer.

Authors:  Stephanie Charshafian; Stephen Y Liang
Journal:  Emerg Med Clin North Am       Date:  2018-06-11       Impact factor: 2.264

3.  Near-universal hospitalization of US emergency department patients with cancer and febrile neutropenia.

Authors:  Christopher W Baugh; Mohammad Kamal Faridi; Emily L Mueller; Carlos A Camargo; Daniel J Pallin
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

4.  Use of MASCC score in the inpatient management of febrile neutropenia: a single-center retrospective study.

Authors:  Prarthna V Bhardwaj; Megan Emmich; Alexander Knee; Fatima Ali; Ritika Walia; Prithwijit Roychowdhury; Jackson Clark; Arthi Sridhar; Tara Lagu; Kah Poh Loh
Journal:  Support Care Cancer       Date:  2021-03-24       Impact factor: 3.359

Review 5.  Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association.

Authors:  Yi Ba; Yuankai Shi; Wenqi Jiang; Jifeng Feng; Ying Cheng; Li Xiao; Qingyuan Zhang; Wensheng Qiu; Binghe Xu; Ruihua Xu; Bo Shen; Zhiguo Luo; Xiaodong Xie; Jianhua Chang; Mengzhao Wang; Yufu Li; Yuerong Shuang; Zuoxing Niu; Bo Liu; Jun Zhang; Li Zhang; Herui Yao; Conghua Xie; Huiqiang Huang; Wangjun Liao; Gongyan Chen; Xiaotian Zhang; Hanxiang An; Yanhong Deng; Ping Gong; Jianping Xiong; Qinghua Yao; Xin An; Cheng Chen; Yanxia Shi; Jialei Wang; Xiaohua Wang; Zhiqiang Wang; Puyuan Xing; Sheng Yang; Chenfei Zhou
Journal:  Cancer Biol Med       Date:  2020-12-15       Impact factor: 4.248

6.  Integrative omics to detect bacteremia in patients with febrile neutropenia.

Authors:  Rachel S Kelly; Jessica Lasky-Su; Sai-Ching J Yeung; Richard M Stone; Jeffrey M Caterino; Sean C Hagan; Gary H Lyman; Lindsey R Baden; Brett E Glotzbecker; Christopher J Coyne; Christopher W Baugh; Daniel J Pallin
Journal:  PLoS One       Date:  2018-05-16       Impact factor: 3.240

7.  Validation of the Clinical Index of Stable Febrile Neutropenia (CISNE) model in febrile neutropenia patients visiting the emergency department. Can it guide emergency physicians to a reasonable decision on outpatient vs. inpatient treatment?

Authors:  Hae Moon; Young Ju Choi; Sung Hoon Sim
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.